Kymera Therapeutics, Inc.

The Company believes these cash, cash equivalents and marketable securities will be sufficient to fund its operations and capital expenditure requirements through at least twelve months from the issuance of these condensed consolidated financial statements.

SEC original ↗Kymera Therapeutics, Inc. — 10-Q Quarterly report10-QOct 29, 2026

The Company expects to finance the future research and development costs of its product portfolio with its existing cash, cash equivalents and marketable securities, or through strategic financing opportunities that could include, but are not limited to future offerings of its equity, collaboration agreements, or the incurrence of debt.

SEC original ↗Kymera Therapeutics, Inc. — 10-Q Quarterly report10-QOct 29, 2026

The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes options-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and the Company s expected dividend yield.

SEC original ↗Kymera Therapeutics, Inc. — 10-Q Quarterly report10-QOct 29, 2026

Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.

SEC original ↗Kymera Therapeutics, Inc. — 10-Q Quarterly report10-QOct 29, 2026

Beyond these clinical programs, our research engine remains focused on unlocking novel biology and pursuing high value targets to build the next wave of oral medicines for patients who need effective, safe and convenient treatment options.

SEC original ↗Kymera Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

• Leveraging its unique target selection strategy, proven small molecule discovery capabilities, and deep development expertise, the Company continues to advance an early pipeline of novel oral programs with a goal to deliver at least one new development candidate per year.

SEC original ↗Kymera Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions.

SEC original ↗Kymera Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about our expectations regarding strategy, business plans and objectives on the development of our clinical and preclinical pipeline, including the therapeutic potential, clinical benefits and safety thereof, the KT-485/SAR447971 and KT-200 programs, and Kymera’s financial condition and expected cash runway into 2029.

SEC original ↗Kymera Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

The Company is a biopharmaceutical company focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body s own natural cellular process, a method known as targeted protein degradation.

SEC original ↗Kymera Therapeutics, Inc. — 10-Q Quarterly report10-QOct 29, 2026

These risks and uncertainties are described in greater detail in the section entitled Risk Factors in the most recent Quarterly Report on Form 10-Q and in subsequent filings with the SEC.

SEC original ↗Kymera Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

A pandemic, epidemic, or outbreak of an infectious disease may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates.

SEC original ↗Kymera Therapeutics, Inc. — 10-Q Quarterly report10-QOct 29, 2026

These statements are not guarantees of future results or performance and involve substantial risks and uncertainties.

SEC original ↗Kymera Therapeutics, Inc. — 10-Q Quarterly report10-QOct 29, 2026

Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and with respect to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.

SEC original ↗Kymera Therapeutics, Inc. — 10-Q Quarterly report10-QOct 29, 2026

Given these uncertainties, you should not place undue reliance on these forward-looking statements.

SEC original ↗Kymera Therapeutics, Inc. — 10-Q Quarterly report10-QOct 29, 2026

An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the Securities and Exchange Commission, or the SEC, could materially and adversely affect our business, prospects, financial condition and results of operations.

SEC original ↗Kymera Therapeutics, Inc. — 10-Q Quarterly report10-QOct 29, 2026